Oxycodone and heroin are both potent opioids that bind to the same receptors in the brain, but they differ sharply in legal status, how they reach the brain, how addictive they are, and what dangers they carry. Oxycodone is a prescription painkiller roughly 1.5 to 2 times as potent as oral morphine, while heroin (chemically known as diamorphine) is estimated at several times morphine’s potency when injected. Those numbers only scratch the surface, though, because potency alone does not predict who gets addicted, who overdoses, or who recovers.
How Potency Stacks Up Against Morphine
Comparing oxycodone and heroin directly is tricky because one is a pill and the other is usually injected or smoked, so researchers typically benchmark each against morphine instead. A controlled study in non-drug-abusing volunteers found that oral oxycodone produced psychopharmacological effects at roughly a third of the oral morphine dose, and the accepted clinical ratio puts oral oxycodone at about 1.5 to 2 times as potent as oral morphine for pain relief.1PubMed Central. Within-subject comparison of the psychopharmacological profiles of oral oxycodone and oral morphine in non-drug-abusing volunteers Heroin, when injected intravenously, is generally considered two to four times as potent as morphine given the same way, largely because it crosses into the brain faster.
But potency comparisons can mislead. A drug that is “stronger” milligram-for-milligram does not necessarily produce a bigger high or a worse addiction. What matters is the full pharmacological profile: how quickly the drug reaches the brain, how it interacts with reward circuits, and what other substances it might be mixed with. On those dimensions, oxycodone and heroin diverge in ways that a simple potency number cannot capture.
Why Oxycodone Stands Out for Addiction Liability
Among prescription opioids, oxycodone appears to carry an unusually high risk of abuse and dependence. A survey of people in treatment for opioid addiction ranked oxycodone as the most “likable” opioid by a wide margin, and mechanistic research has started to explain why: oxycodone is actively transported across the blood-brain barrier more efficiently than many other opioids, it triggers stronger bursts of dopamine in the brain’s reward centers, and it may produce more intense withdrawal discomfort through its effects on kappa opioid receptors.2SpringerLink. Oxycodone’s Unparalleled Addictive Potential: Is it Time for a Moratorium? The same study that found oxycodone was 1.5 to 2 times as potent as morphine for pain also noted that patients receiving oxycodone may be experiencing “stronger and potentially different psychopharmacological effects” beyond just pain relief, including more euphoria and subjective drug liking.1PubMed Central. Within-subject comparison of the psychopharmacological profiles of oral oxycodone and oral morphine in non-drug-abusing volunteers
Heroin, of course, is also intensely addictive. Its advantage from a pharmacological standpoint is speed: injected heroin floods the brain in seconds, producing a rush that is hard for oral oxycodone to match. When people crush and snort or inject oxycodone pills, they partially close that gap. Intranasal oxycodone reaches peak blood levels in a median time of about 25 minutes, which is much faster than swallowing a pill but still slower than the near-instant onset of injected heroin.3PubMed. Pharmacokinetic comparison of intravenous and intranasal administration of oxycodone Speed of onset matters enormously for addiction because the brain learns to associate the drug with reward more strongly when the effect is immediate.
Overdose Risk and What Makes Each Drug Dangerous
Both drugs kill the same way: they suppress the brainstem’s drive to breathe. The dose at which that happens varies with tolerance, body weight, and what else someone has taken. But the practical risk landscape is quite different for the two drugs.
With prescription oxycodone, the dose is known. A 30 mg pill contains 30 mg. The danger escalates when someone takes more than prescribed, combines pills with alcohol or benzodiazepines, or has a genetic variation that alters how fast they metabolize the drug. Between 2015 and 2017, benzodiazepines were found alongside prescription opioids in roughly a third of fatal prescription opioid overdoses, a higher co-involvement rate than in overdoses involving heroin or synthetic opioids like fentanyl.4JAMA Network Open. Alcohol or Benzodiazepine Co-involvement With Opioid Overdose Deaths in the United States, 1999-2017 The combination of an opioid with a sedative like a benzodiazepine or alcohol is especially lethal because both classes of drug independently slow breathing.
With heroin, the risk profile shifts. The dose is unknown. Street heroin varies wildly in purity, and over the past decade the illicit supply has been increasingly contaminated with fentanyl and other synthetic opioids that are dozens of times more potent than heroin itself. During that same 2015-to-2017 window, synthetic opioids were involved in nearly half of all opioid overdose deaths in the United States.4JAMA Network Open. Alcohol or Benzodiazepine Co-involvement With Opioid Overdose Deaths in the United States, 1999-2017 Someone who has built a tolerance to heroin at a particular dose can easily overdose if their next batch contains fentanyl they do not know about. This unpredictability is one of the biggest differences in real-world risk between prescription oxycodone and street heroin.
How Naloxone Works Against Each Drug
Naloxone (sold under brand names like Narcan) reverses opioid overdoses by knocking opioid molecules off the brain’s mu-opioid receptors. It works against both oxycodone and heroin, but the details matter in an emergency. For a straightforward heroin overdose, an initial injection of 0.4 to 0.8 mg of naloxone is usually enough to restore breathing.5PubMed Central. Clinical Pharmacokinetics and Pharmacodynamics of Naloxone
The complication is that naloxone wears off faster than most opioids. Someone who has taken a large dose of a long-acting oxycodone formulation, or who has a large amount of heroin still being metabolized, can slip back into respiratory depression after the naloxone fades. This phenomenon, called re-narcotization, is a recognized risk with any opioid overdose, but it is especially dangerous with extended-release oxycodone products and with fentanyl-laced heroin, where the opioid load is high and sustained.6PubMed Central. Naloxone dosage for opioid reversal: current evidence and clinical implications Anyone who receives naloxone needs to be monitored afterward, even if they seem to have recovered. The goal of naloxone is to restore breathing, not necessarily full consciousness, and rushing the dose can throw someone into acute withdrawal.5PubMed Central. Clinical Pharmacokinetics and Pharmacodynamics of Naloxone
The Pipeline from Prescription Pills to Heroin
One of the defining features of the opioid crisis has been the trajectory from legal prescription opioids to illicit heroin and fentanyl. Case studies of people who made this transition describe a common pattern: oral use of prescription painkillers escalates to crushing and snorting or injecting those same pills, and eventually the person switches to heroin because it is cheaper, more available, or delivers a faster high.7PubMed Central. The Evolving Consequences of OxyContin Reformulation on Drug Overdoses Individual case reports have documented this progression in detail, with young people moving through a range of pharmaceutical opioids before transitioning to intravenous heroin.8Wiley Online Library. From oxycodone to heroin: two cases of transitioning opioid use in young Australians
The reformulation of OxyContin in 2010, which made the pills harder to crush and snort, is a case study in unintended consequences. Research comparing states that had higher rates of OxyContin misuse before the reformulation to those with lower rates found that the more exposed areas did not just see a rise in heroin deaths. Over a longer horizon, those areas also saw disproportionate increases in fatal overdoses involving fentanyl and even non-opioid drugs like cocaine, suggesting that disrupting the prescription supply pushed people into broader and more dangerous illicit markets.7PubMed Central. The Evolving Consequences of OxyContin Reformulation on Drug Overdoses The lesson is uncomfortable: making one drug harder to abuse can scatter demand across a more dangerous and less predictable drug supply.
Treatment Outcomes Differ by Drug
When people seek treatment for opioid dependence, the substance they were using predicts how well treatment goes. In a study of office-based buprenorphine treatment, patients who were dependent on prescription opioids only were about twice as likely to complete treatment as those dependent on heroin only (roughly 59% versus 30%). Prescription-opioid patients stayed in treatment longer, averaging 21 weeks compared to about 14 weeks for heroin-only patients, and had a higher rate of opioid-negative urine tests during treatment.9PubMed Central. Primary care office-based buprenorphine treatment: comparison of heroin and prescription opioid dependent patients
People who used both heroin and prescription opioids fell in between the two groups on every measure. The reasons for the gap are not fully understood, but likely involve a mix of factors: heroin-dependent patients tend to have been using for longer, are more likely to inject (which is associated with more severe dependence), and often face more social instability. The takeaway is not that heroin dependence is untreatable, but that clinicians may need to anticipate longer treatment courses and more intensive support for patients transitioning off heroin compared to those coming off prescription opioids.
How Drug Tests Tell Them Apart
Standard urine drug panels can detect opioid use but distinguishing heroin from other opioids requires more specific testing. Heroin itself is broken down so quickly in the body that it is virtually undetectable. Instead, labs look for its unique metabolite, 6-monoacetylmorphine (6-MAM), which confirms heroin use specifically. The problem is that 6-MAM also disappears fast, giving a narrow window for detection.
A study that tracked heroin metabolites in urine found that while 6-MAM vanishes within hours to a couple of days, another metabolite called morphine-3-glucuronide (M3G) was still detectable 9 to 11 days after the last heroin use in 40% of the participants tested. M3G was present at much higher concentrations than plain morphine and had the longest detection window of the metabolites studied.10Journal of Analytical Toxicology. Comparison of the Detection Windows of Heroin Metabolites in Human Urine Using Online SPE and LC–MS/MS: Importance of Morphine-3-Glucuronide For forensic and clinical purposes, combining M3G with other contextual evidence could improve the accuracy of heroin-use detection beyond what 6-MAM alone provides.
Oxycodone, by contrast, is straightforward to identify in urine because it has its own distinct metabolites (oxymorphone, noroxycodone). Standard immunoassay panels for opioids sometimes miss oxycodone entirely because they are calibrated to detect morphine-type opioids, so a confirmatory test specifically targeting oxycodone is often needed. If you are taking prescribed oxycodone and undergoing drug testing, this is worth knowing: a basic screen might come back negative for opioids even when you have been taking them as directed.
Legal Status and Medical Use Around the World
Oxycodone is a Schedule II controlled substance in the United States, meaning it has accepted medical uses but carries high abuse potential. It is prescribed for moderate to severe pain, particularly in cancer care. In the UK, prescribing patterns over a nine-year period showed a rise in oxycodone use among cancer patients in the last months of life, alongside morphine and fentanyl.11PubMed. Opioid prescribing for cancer pain during the last 3 months of life: associated factors and 9-year trends in a nationwide United Kingdom cohort study
Heroin’s legal status is more varied than most people realize. In the United States, heroin is Schedule I, meaning it is considered to have no accepted medical use. But in the United Kingdom, pharmaceutical-grade heroin (called diamorphine) is a licensed medication used for severe pain and palliative care.12BMJ Supportive & Palliative Care. Diamorphine for pain and distress in young patients: case examples and discussion of mechanisms Switzerland and a few other countries have heroin-assisted treatment programs where people with severe, treatment-resistant addiction receive pharmaceutical-grade heroin in supervised clinical settings. The contrast between countries where the same molecule is either standard medicine or a symbol of criminal deviance illustrates how much of what we think of as a drug’s “nature” is shaped by law and culture rather than by chemistry alone.
How Race and Stigma Shape the Two Drug Crises
The social histories of oxycodone and heroin are inseparable from race in America. When prescription opioid misuse surged in the 1990s and 2000s, it was framed largely as a medical problem affecting white suburban and rural communities. Researchers have traced how a set of interlinked forces, including pharmaceutical marketing, legislative choices, and neuroscience framing, carved out a less punitive, clinical approach to white drug use while leaving more punitive systems in place for communities of color.13PubMed Central. White opioids: Pharmaceutical race and the war on drugs that wasn’t
Media coverage reinforced the divide. A content analysis of 100 popular press articles found a consistent pattern: heroin users were portrayed as criminalized, urban, Black, and Latino, while prescription opioid users were depicted sympathetically as suburban, white, and in need of medical help. This distinction echoed earlier disparities in how crack cocaine and powder cocaine were treated in law and public discourse.14PubMed Central. The War on Drugs That Wasn’t: Wasted Whiteness, “Dirty Doctors,” and Race in Media Coverage of Prescription Opioid Misuse The practical consequence is that a person struggling with oxycodone dependence has historically been more likely to be offered treatment, while a person struggling with heroin dependence has been more likely to be offered handcuffs, even when the pharmacology of their problem is essentially the same.
These disparities have real health consequences. If stigma keeps heroin-dependent people from seeking treatment, and if the treatment they eventually receive is less supportive, the worse treatment-completion rates documented in the buprenorphine study cited earlier become at least partly a reflection of structural barriers rather than purely pharmacological differences between the two drugs. The science cannot be separated from the social context in which these drugs are used, prescribed, policed, and treated.
Metabolism and Why Individual Responses Vary
Both oxycodone and heroin are transformed in the body by enzymes before they produce their effects, and genetic variation in those enzymes helps explain why two people can take the same dose and have very different experiences. Oxycodone is metabolized primarily in the liver, where certain cytochrome P450 enzymes convert it into active and inactive metabolites. People who carry genetic variants that make these enzymes more or less active can end up with unexpectedly high or low drug levels from a standard dose. The same general principle applies to heroin and its rapid conversion to morphine, which is then further metabolized by glucuronyltransferases and other enzymes.15PubMed Central. Absorption, distribution, metabolism and excretion pharmacogenomics of drugs of abuse
This variability has practical implications beyond just how “high” someone gets. A person who metabolizes oxycodone unusually fast may burn through a dose before the next one is due, entering early withdrawal and inadvertently escalating their use. A person who metabolizes it slowly may accumulate dangerous blood levels on what their doctor considers a conservative dose. Pharmacogenomic testing can identify some of these variations, though it is still not routinely used outside of specialty pain clinics. For heroin users, genetic variability is compounded by the unpredictable potency of street supply, making individual metabolic differences just one more layer of risk on top of an already chaotic situation.
Fentanyl and the Blurring of the Old Distinction
The traditional line between “prescription opioid problem” and “heroin problem” has been increasingly blurred by synthetic opioids, primarily illicitly manufactured fentanyl. Fentanyl now contaminates large portions of the heroin supply, and in many urban markets what is sold as heroin contains little or no actual heroin at all. But fentanyl has also turned up in counterfeit prescription pills made to look like oxycodone, hydrocodone, or other pharmaceutical opioids. A person who thinks they are buying a diverted prescription oxycodone pill on the street may actually be taking a pressed fentanyl tablet with an unknown dose.
Research on the aftermath of the 2010 OxyContin reformulation showed that disrupting the prescription opioid supply did not just shift people to heroin. It stimulated the growth and evolution of illicit drug markets in ways that led to disproportionate increases in synthetic opioid deaths in the areas most affected.7PubMed Central. The Evolving Consequences of OxyContin Reformulation on Drug Overdoses The result is a landscape where the old categories barely apply. A person buying what they believe is oxycodone and a person buying what they believe is heroin may both be taking fentanyl, and the risk profile for both has converged around the same lethal variable: an unknown dose of an extraordinarily potent synthetic opioid mixed into whatever they thought they were getting.